Answers are grounded in this paper and cite their sources.
These findings suggest that thalamic atrophy is a clinically relevant biomarker of the neurodegenerative disease process in multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Houtchens et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: